Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2018-11-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
独立董事关于公司第七届董事会第十三次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a board meeting resolution regarding a related-party transaction and establishment of a medical industry investment fund. It references compliance with company law, securities law, and stock exchange listing rules. The content is about the board meeting's deliberation and approval process, focusing on governance and fairness of the transaction. It is not a full financial report, audit report, or earnings release. It is not a simple announcement of voting results but an independent opinion related to board decisions. This fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information related to governance and transactions.
2018-11-21 Chinese
第七届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 7th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and voting results on specific proposals, including a related-party transaction and the calling of an extraordinary general meeting. The document references compliance with laws and company bylaws and mentions that further details will be published in designated newspapers and on a specified website. The content focuses on board meeting decisions rather than full financial reports or other types of filings. Given the nature of the document as an announcement of board meeting resolutions, it fits the category of Board/Management Information (MANG). The document length is short (1261 characters), and it is not a report itself but an announcement of board decisions, so it is not an Annual Report or Management Report. Therefore, the classification is MANG with high confidence.
2018-11-21 Chinese
关于控股子公司南京鼓楼医院集团仪征医院老病房大楼改造项目的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding an investment project by its controlling subsidiary, Nanjing Gulou Hospital Group Yizheng Hospital, to renovate an old inpatient building. It includes details about the investment amount, board approval, project description, risks, and expected impact on the company. The document is relatively short (2059 characters) and does not contain financial statements or detailed financial data. It is an announcement of an investment project rather than a financial report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or voting result. The content aligns best with a Capital/Financing Update (CAP) as it informs about a significant investment and capital expenditure by a subsidiary. Therefore, the appropriate classification is CAP with high confidence.
2018-11-12 Chinese
第七届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Jinling Pharmaceutical Co., Ltd. It details the convening of the 12th meeting of the 7th Board of Directors, the approval of a project related to a subsidiary, and the voting results. There is no financial data, no detailed report, and no indication that this is a full annual or interim report. The document is an official announcement of board decisions, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2018-11-12 Chinese
第七届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 10th meeting of the 7th Supervisory Board of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting notice, date, method, attendance, compliance with laws and regulations, the agenda item approved, and voting results. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, no capital or financing updates, and no other report types. The document is a corporate governance announcement related to board/supervisory meeting resolutions. This fits best under Board/Management Information (MANG) as it concerns internal governance decisions and meeting outcomes. The document length is short and it is not an announcement of a report publication but a direct disclosure of meeting resolutions. Therefore, the classification is MANG with high confidence.
2018-11-12 Chinese
2018年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 Third Quarter Report" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the quarter, including assets, liabilities, income, profit, cash flows, and shareholder information. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2018
2018-10-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.